(NYSE: BHVN) Biohaven's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.4%.
Biohaven's revenue in 2026 is $0.On average, 17 Wall Street analysts forecast BHVN's revenue for 2026 to be $4,902,125,912, with the lowest BHVN revenue forecast at $0, and the highest BHVN revenue forecast at $55,508,589,518. On average, 19 Wall Street analysts forecast BHVN's revenue for 2027 to be $7,513,672,886, with the lowest BHVN revenue forecast at $0, and the highest BHVN revenue forecast at $25,851,143,118.
In 2028, BHVN is forecast to generate $15,803,710,806 in revenue, with the lowest revenue forecast at $3,647,254,180 and the highest revenue forecast at $32,131,543,532.